TUSTIN, Calif., Nov. 23 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL
- News), headquartered in Tustin, California, with operations in Shenzhen,
Jiangxi and Jilin, China, through its wholly owned subsidiary Jade
Pharmaceutical Inc. (JPI), is an international biopharma company that
engages in the development, manufacture and marketing of proprietary
pharmaceutical and diagnostic products. The Company announced today that
the recent presentation by its CEO, Gary Dreher, at the prestigious 9th
Annual Healthcare Conference sponsored by the full-service investment bank,
Rodman & Renshaw, and its life science division, Acumen BioFin,(TM) is now
available at WallStreetRepoter.com.
The link to listen to the presentation is at http://www.wallstreetreporter.com/page.php?page=view_videos&id=134
Mr. Dreher noted that "AMDL recently announced that it had sales of approximately $5.8 million for the third quarter of 2007 compared to $2.3 million for the second quarter of 2007 with $0.05 per share in earnings. AMDL's introduction of new products and increased distribution channels caused the upturn in revenues and profits. This marked AMDL's first quarter with positive cash flow and net earnings. These superior results indicate that we anticipate that our Chinese subsidiaries will continue to experience strong sales and gross profit growth that will greatly improve AMDL's combined operating results."
About JPI: Jade Pharmaceutical has access to the fastest growing
pharmaceutical and consumer market in the world: China. AMDL, through its
subsidiary, Jade currently manufactures large volume injectable fluids,
tablets and other related products, holding licenses for 133 products. It
also manufactures 107 generic, over the counter and supplemental
pharmaceutical products under certified Chinese Good Manufacturing Practice
About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com .
Contact: AMDL, Inc.
AMDL Investor Relations
Direct Line: 949.707.5365
Voice Mail: 714.505.4460
|SOURCE AMDL, Inc.|
Copyright©2007 PR Newswire.
All rights reserved